消化不良药物市场：按类型、药物类型、分销管道划分 - 全球预测 2025-2030

2023年消化不良治疗市场价值为85.8亿美元，预计到2024年将达到90.1亿美元，复合年增长率为5.12%，到2030年将达到121.8亿美元。

胃肠道药物是更广泛的胃肠道药物市场的重要组成部分，旨在控制胃部不适、腹胀和噁心等症状。全球功能性消化不良的高盛行率凸显了对这些药物的需求，而不良饮食和压力等生活方式因素又加剧了这种情况。这些药物用于医院、诊所和居家医疗机构，以帮助短期症状缓解和慢性病的长期管理。市场成长的主要驱动因素包括人口老化、胃肠道疾病盛行率上升以及配方和药物输送系统的进步。新兴市场的医疗保健意识和获取机会的提高也是市场扩张的沃土。开发新的、更有效的化合物和以患者为中心的解决方案，包括非处方药，代表着一个重大机会，可以利用消费者对更容易获得的医疗保健日益增长的偏好。然而，药物开发的高成本、严格的监管流程和潜在的副作用等限制因素构成了重大挑战。此外，来自替代疗法和营养食品的竞争也阻碍了市场成长。为了克服这些挑战，创新应侧重于精准医疗以及人工智慧主导的诊断和个人化治疗计划等数位健康技术的集成，从而提高药物疗效和患者依从性。鑑于对整体医疗保健解决方案的需求不断增长，投资强大的研发策略以实现益生菌和天然萃取物的药物组合多样化可能是我的策略重点。市场动态是动态的和竞争性的，需要与医疗保健专业人员和患者持续接触，以确定未满足的需求并适应不断变化的消费者偏好。为了保持优势，公司应该投资消费者教育并与监管机构建立牢固的工作关係，以促进更顺利的市场进入和扩张。

市场动态：快速发展的消化不良药物市场的关键市场洞察

消化不良药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

• 市场驱动因素
  • 消化不良的盛行率在世界各地迅速增加
  • 支持加速医药品认证过程的政府政策
  • 投资改良药物输送和包装技术
• 市场限制因素
  • 产品召回与安全问题
• 市场机会
  • 透过共同开发和官民合作关係扩大发展
  • 提高药效的研发进展
• 市场挑战
  • 假药的可用性

波特五力：驾驭消化不良药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解消化不良药物市场的外部影响

外部宏观环境因素在塑造消化不良药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解消化不良治疗市场的竞争状况

对消化不良治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵消化不良药物市场供应商的绩效评估

FPNV定位矩阵是评估消化不良药物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划消化不良治疗药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，消化不良治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 全球消化不良盛行率飙升
    • 支持加速药品核准流程的政府政策
    • 投资改良药物输送和包装技术
  • 抑制因素
    • 产品召回与安全问题
  • 机会
    • 透过联合开发和公私合营进行扩张
    • 提高药物疗效的研发进展
  • 任务
    • 假药的可用性
• 市场区隔分析
  • 类型：功能性消化不良的广泛发生和转向更个性化的药物
  • 药物类型：越来越多地使用质子帮浦阻断剂和H2受体阻断剂来治疗消化不良
• 波特五力分析
• PESTEL分析
  • 政治的
  • 经济
  • 社群
  • 技术的
  • 合法地
  • 环境

第六章消化不良治疗药物市场：依类型

• 功能性消化不良
• 器质性消化不良

第七章消化不良治疗药物市场（按类型）

• 抑酸剂
• 制酸剂
• 抗生素
• 抗惊厥药
• 抗忧郁症
• 西咪替丁
• 法莫替丁
• H2拮抗剂
• 尼扎替丁
• 消化促进剂
• 质子帮浦抑制剂
• Rabeprazole
• 赞塔克

第八章消化不良治疗药物市场：按分销管道

• 医院药房
• 网路药房
• 零售药房

第九章北美及南美消化不良药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第十章亚太消化不良治疗市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十一章 欧洲、中东和非洲消化不良治疗市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十二章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
  • 突破性 FDA核准，Fathom Pharmaceuticals 推出 VOQUEZNA，治疗糜烂性胃食道逆流症
  • 剪切机-Smith推出法莫替丁口服混悬剂是美国学名药市场的策略性倡议。
  • Mark Sands Pharma非专利药法莫替丁锭获得美国FDA核准
• 战略分析和建议

公司名单

• Abbott Laboratories
• ANI Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bayer AG
• Cadila Pharmaceuticals
• Dr Reddy's Laboratories Ltd
• Haleon PLC
• Intas Pharmaceuticals Ltd.
• Lupin Ltd.
• Mankind Pharma
• Pfizer Inc.
• Prestige Consumer Healthcare Inc.
• Procter & Gamble Company
• Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Themis Medicare Ltd.
• Torrent Pharmaceuticals Ltd.

The Dyspepsia Drug Market was valued at USD 8.58 billion in 2023, expected to reach USD 9.01 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 12.18 billion by 2030.

Dyspepsia drugs form a crucial segment within the broader gastrointestinal therapeutics market, aimed at managing symptoms like stomach discomfort, bloating, and nausea. The necessity for these drugs is underscored by the high prevalence of functional dyspepsia worldwide, exacerbated by lifestyle factors such as poor diet and stress. These drugs find applications across hospitals, clinics, and homecare settings, serving both short-term symptomatic relief and long-term management of chronic conditions. Key drivers of market growth include an aging population, the rising incidence of gastrointestinal disorders, and ongoing advancements in drug formulations and delivery systems. Increasing healthcare awareness and access in emerging markets also provide fertile ground for market expansion. A prominent opportunity lies in the development of novel, more efficacious drug compounds and patient-centered solutions, including over-the-counter options, potentially tapping into the growing consumer preference for accessible healthcare solutions. However, limitations like the high cost of drug development, stringent regulatory processes, and potential side effects pose significant challenges. Additionally, market growth is hampered by competition from alternative therapies and dietary supplements. To overcome these challenges, innovation should focus on precision medicine and the integration of digital health technologies, such as AI-driven diagnostics and personalized treatment plans, thus enhancing drug efficacy and patient adherence. Investing in robust R&D strategies to diversify the drug portfolio with probiotics and natural extracts could be a strategic pivot, considering the rising demand for holistic healthcare solutions. The nature of the dyspepsia drug market is dynamic and competitive, necessitating continuous engagement with healthcare professionals and patients to identify unmet needs and adapt to evolving consumer preferences. To maintain an edge, companies should invest in consumer education and build strong collaborations with regulatory bodies to facilitate smoother market entry and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dyspepsia Drug Market

The Dyspepsia Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surging prevalence of Dyspepsia worldwide
  • Government policies favoring faster drug approval processes
  • Investment in improved drug delivery and packaging technologies
• Market Restraints
  • Product recall and safety concerns
• Market Opportunities
  • Expansion through collaborative development and public-private partnerships
  • Advancements in research and development for enhanced drug efficacy
• Market Challenges
  • Availability of the counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Dyspepsia Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dyspepsia Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dyspepsia Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dyspepsia Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dyspepsia Drug Market

A detailed market share analysis in the Dyspepsia Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dyspepsia Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dyspepsia Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dyspepsia Drug Market

A strategic analysis of the Dyspepsia Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dyspepsia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Cadila Pharmaceuticals, Dr Reddy's Laboratories Ltd, Haleon PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Mankind Pharma, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Dyspepsia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Functional Dyspepsia and Organic Dyspepsia.
• Based on Drug Type, market is studied across Acid Reducer, Antacids, Antibiotics, Anticonvulsant, Antidepressants, Cimetidine, Famotidine, H2 Antagonist, Nizatidine, Prokinetic agent, Proton-pump Inhibitor, Rabeprazole, and Zantac.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surging prevalence of Dyspepsia worldwide
    • 5.1.1.2. Government policies favoring faster drug approval processes
    • 5.1.1.3. Investment in improved drug delivery and packaging technologies
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall and safety concerns
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion through collaborative development and public-private partnerships
    • 5.1.3.2. Advancements in research and development for enhanced drug efficacy
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of the counterfeit drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Wide occurrence of functional dyspepsia with the shift towards more personalized drugs
  • 5.2.2. Drug Type: Growing utilization of proton pump inhibitors and H2 receptor blockers for dyspepsia treatment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dyspepsia Drug Market, by Type

• 6.1. Introduction
• 6.2. Functional Dyspepsia
• 6.3. Organic Dyspepsia

7. Dyspepsia Drug Market, by Drug Type

• 7.1. Introduction
• 7.2. Acid Reducer
• 7.3. Antacids
• 7.4. Antibiotics
• 7.5. Anticonvulsant
• 7.6. Antidepressants
• 7.7. Cimetidine
• 7.8. Famotidine
• 7.9. H2 Antagonist
• 7.10. Nizatidine
• 7.11. Prokinetic agent
• 7.12. Proton-pump Inhibitor
• 7.13. Rabeprazole
• 7.14. Zantac

8. Dyspepsia Drug Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Dyspepsia Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Dyspepsia Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Dyspepsia Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Breakthrough FDA Approval, Phathom Pharmaceuticals Unveils VOQUEZNA for Erosive GERD Treatment
  • 12.3.2. Launch of Upsher-Smith's Famotidine for Oral Suspension, A Strategic Move in the U.S. Generic Drug Market
  • 12.3.3. Marksans Pharma Secures USFDA Approval for Generic Famotidine Tablets
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ANI Pharmaceuticals, Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Cadila Pharmaceuticals
• 6. Dr Reddy's Laboratories Ltd
• 7. Haleon PLC
• 8. Intas Pharmaceuticals Ltd.
• 9. Lupin Ltd.
• 10. Mankind Pharma
• 11. Pfizer Inc.
• 12. Prestige Consumer Healthcare Inc.
• 13. Procter & Gamble Company
• 14. Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International
• 15. Sanofi SA
• 16. Sun Pharmaceutical Industries Ltd.
• 17. Takeda Pharmaceutical Company Limited
• 18. Themis Medicare Ltd.
• 19. Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

• FIGURE 1. DYSPEPSIA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. DYSPEPSIA DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DYSPEPSIA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DYSPEPSIA DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORGANIC DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ACID REDUCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETIC AGENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON-PUMP INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ZANTAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. CANADA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. CHINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. INDIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. ITALY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. POLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. QATAR DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 156. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023